All In Biotech

Drug Trial Radar · NCT01076010

An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).

An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301).

Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

277

Actual

Start

Mar 2010

Primary completion

Jul 2014

Study completion Jul 2014

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 25, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, multi-center extension treatment protocol to allow access to tivozanib and sorafenib for subjects who have participated on the AV-951-09-301 protocol. Eligible subjects who were randomized to receive sorafenib on AV-951-09-301 and had documented progression of disease will receive a tivozanib dose of 1.5 mg/day. Eligible subjects who were randomized to tivozanib or sorafenib in AV-951-09-301, and displayed clinical benefit and acceptable tolerability to treatment, will continue to receive tivozanib or sorafenib at the same dose and schedule as in AV-951-09-301.

Conditions

  • Advanced Renal Cell Carcinoma

Interventions

  • TivozanibDrug

    Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.

  • SorafenibDrug

    Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Days Subjects Received Treatment in Each Treatment ArmTime frame: From enrollment to until all subjects discontinue (due to documented progressive disease [PD] or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
  2. Number of Cycles Subjects Received Treatment in Each Treatment ArmTime frame: From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
  3. Total Dose Administered to Subjects in Each Treatment Arm (mg)Time frame: From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
  4. Average Daily Dose Administered to Subjects in Each Treatment ArmTime frame: From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
  5. Relative Dose Intensity (RDI) of Treatment Administered to Subjects in Each Treatment ArmTime frame: From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
  6. Number of Subjects With Adverse EventsTime frame: From enrollment assessed up to 3 years of treatment or until follow-up (up to 30 days end-of-trial visit after treatment discontinuation), whichever occurs earlier

Locations

75 sites in 15 countries. Site status is shown where the registry gives one.

  • Site 185

    Los Angeles, California

  • Site 184

    Orlando, Florida

  • Site 182

    Minneapolis, Minnesota

  • Site 186

    New York, New York

  • Site 187

    Dallas, Texas

  • Site 403

    Plovdiv, Bulgaria

  • Site 404

    Sofia, Bulgaria

  • Site 400

    Sofia, Bulgaria

  • Site 401

    Varna, Bulgaria

  • Site 402

    Veliko Tarnovo, Bulgaria

  • Site 110

    Montreal, Quebec, Canada

  • Site 122

    Santiago, Chile

  • Site 123

    Temuco, Chile

  • Site 411

    Prague, Czechia

  • Site 133

    Saint-Herblain, France

  • Site 423

    Budapest, Hungary

  • Site 421

    Kaposvár, Hungary

  • Site 422

    Pécs, Hungary

  • Site 154

    Delhi, India

  • Site 156

    Ahmedabad, Gujarat, India

  • Site 151

    Nashik, Maharashtra, India

  • Site 153

    Pune, Maharashtra, India

  • Site 191

    Jaipur, Rajasthan, India

  • Site 152

    Vellore, Tamil Nadu, India

  • Site 158

    Lucknow, Uttar Pradesh, India

  • Site 150

    Kolkata, West Bengal, India

  • Site 160

    Arezzo, Italy

  • Site 161

    Pavia, Italy

  • Site 162

    Roma, Italy

  • Site 432

    Bialystok, Poland

  • Site 434

    Bydgoszcz, Poland

  • Site 431

    Gdansk, Poland

  • Site 435

    Olsztyn, Poland

  • Site 433

    Poznan, Poland

  • Site 430

    Warsaw, Poland

  • Site 436

    Warsaw, Poland

  • Site 444

    Brasov, Romania

  • Site 441

    Bucharest, Romania

  • Site 440

    Bucharest, Romania

  • Site 443

    Bucharest, Romania

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.